Cargando…
Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females
A surprising result of the groundbreaking CAPRISA-004 trial, which demonstrated the efficacy of vaginal tenofovir 1% gel in reducing the risk of human immunodeficiency virus (HIV)-1 infection by 39% in heterosexual women, was the added benefit of this microbicide in reducing acquisition of herpes si...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422111/ https://www.ncbi.nlm.nih.gov/pubmed/22927765 http://dx.doi.org/10.2147/IJWH.S27601 |